-
Jefferies Projects $573M Peak Sales For Cara Therapeutics' Lead Candidate
Thursday, September 13, 2018 - 11:55am | 388Read More...Cara Therapeutics Inc (NASDAQ: CARA), a biotech company developing non-opioid pain relief drugs, has earned a bullish review from Jefferies. The Analyst Analyst Matthew Andrews initiated coverage of Cara with a Buy rating and $30 price target. The Thesis Cara's lead program is...
-
Potential FDA Controversy Brewing For TG Therapeutics?
Tuesday, April 25, 2017 - 11:40am | 329Read More...TG Therapeutics Inc (NASDAQ: TGTX), a small-cap biopharmaceutical company focusing on treatments for B-cell malignancies and autoimmune diseases, was initiated with a Buy rating and $23 price target by analysts at Jefferies. Jefferies' Matthew Andrews commented in a research report on Tuesday,...
-
Looking For The Positives In TherapeuticsMD's Recently Received FDA Letter
Tuesday, April 11, 2017 - 2:06pm | 388Read More...TherapeuticsMD Inc (NYSE: TXMD) shares are down another 7.0 percent on Tuesday after a 19.4 percent drop Monday on news that the company received a letter from the U.S. Food and Drug Administration noting “deficiencies” in the company’s TX-004 drug candidate. TX-004 is an estrogen...
-
Jefferies Sees Accelerated Approval Of Immunomedics' IMMU-132 'Not A Stretch'
Thursday, October 6, 2016 - 11:43am | 275Read More...Jefferies assumed coverage of Immunomedics, Inc. (NASDAQ: IMMU) with a Buy rating and $5.50 price target, saying shares are undervalued ahead of a partnership announcement on IMMU-132. The company is in the process of completing various activities to support the Phase III study of sacituzumab...
-
Mixed Response on Infinity Pharma as Shares Plunge Amid Phase I Data
Monday, June 3, 2013 - 1:42pm | 174Read More...In reports published on Monday, Wells Fargo analyst Matthew Andrews and Piper Jaffray analyst Ian Somaiya had mixed responses on Infinity Pharma (NASDAQ: INFI) CLL drug data. Wells Fargo calls the data "Very Solid" as its Phase 1/2 data on IPI-145 in chronic lymphocytic leukemia (CLL)...
